Imagine living with a kidney disease that makes you feel constantly unwell and limits your daily life. For many, primary focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) can feel like an uphill battle, as current treatments don’t work for everyone. This study is exploring three new drugs—frexalimab, brivekimig, and rilzabrutinib—to see if they can effectively reduce protein in urine, a key indicator of kidney health. Over 76 weeks, participants will receive one of these treatments or a placebo, with the hope of finding a better way to manage their symptoms. If these drugs prove effective, they could lead to fewer people experiencing the debilitating effects of nephrotic syndrome, which is often tied to these kidney diseases. However, it's important to remember that these treatments are still in the testing phase, and we need to wait for the results to understand their true impact. The journey to better kidney health continues, and this research offers a glimmer of hope for those affected.
Phase 2 Study Evaluates Frexalimab, Brivekimig, Rilzabrutinib in FSGS and MCDCould New Treatments Help Those Struggling with Kidney Disease?
AI-generated summary of the cited source, checked by automated accuracy review. How we work
Key Takeaway
Monitor for updates on proteinuria reduction in FSGS and MCD with these novel agents.
This Phase 2a, double-blind, parallel, 6-arm study aims to evaluate the efficacy and safety of frexalimab, brivekimig, and rilzabrutinib in patients aged 16 to 75 years with primary focal segmental glomerulosclerosis (FSGS) or primary minimal change disease (MCD). The study will enroll 84 participants and will last up to 76 weeks, with a treatment duration of 24 weeks. Participants will attend up to 18 visits. The primary endpoint is the percent reduction in urine protein to creatinine ratio (UPCR), which serves as a measure of proteinuria reduction. Secondary endpoints and detailed safety profiles will be assessed, although specific statistics such as hazard ratios, odds ratios, or confidence intervals are not yet available. The trial is sponsored by Sanofi and is currently recruiting, with an estimated primary completion date of December 23, 2026. The study's outcomes could potentially inform treatment strategies for FSGS and MCD, focusing on reducing proteinuria as a key therapeutic target.
What this means for you:
New treatments for kidney disease could lead to better management and improved lives for patients. More on Focal Segmental Glomerulosclerosis
Rituximab Shows Long-Term Remission in Pediatric Steroid-Dependent Nephrotic Syndrome
Rituximab Helps Kids With Kidney Swelling
This retrospective cohort study of 42 children with steroid-dependent or frequently relapsing nephrotic syndrome found that rituximab led to…
Imagine a child who needs medicine just to stay dry.
Frexalimab study validates PROMIS-Fatigue-MS-8a and MSIS-29v2 in relapsing multiple sclerosis patients
New tools reliably measure fatigue in multiple sclerosis
This Phase 2 trial assessed psychometric validation of PROMIS-Fatigue-MS-8a and MSIS-29v2 in adults with relapsing multiple sclerosis.
Two questionnaires accurately track fatigue in relapsing MS, offering a new way to measure treatment benefits in trials.
Rituximab pharmacokinetics vary widely in membranous nephropathy, minimal change disease, and lupus nephritis patients
Rituximab Works — But Only If Your Body Keeps Enough of It
This review examined pharmacokinetic profiling of rituximab in patients with glomerular diseases.
Rituximab helps kidney disease patients only if their bodies keep enough of it in the blood, since some people clear the drug too fast and g…
Obinutuzumab induced remission in FSGS patient after rituximab failure in case report
Obinutuzumab helped one patient with kidney disease after rituximab did not work
A case report describes a 33-year-old woman with primary FSGS and nephrotic syndrome who achieved complete remission after obinutuzumab foll…
When rituximab failed to stop protein leakage in a kidney disease patient, a single dose of obinutuzumab restored remission without side eff…
View Original Abstract ↓
Status: RECRUITING | Phase: PHASE2
Condition(s): Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion
Intervention(s): frexalimab (DRUG), brivekimig (DRUG), rilzabrutinib (DRUG), placebo (DRUG)
This is a parallel, Phase 2a, double-blind, 6-arm study for the treatment of primary focal segmental glomerulosclerosis (FSGS) or primary minimal change disease (MCD).
The purpose of this study is to measure the change in proteinuria and its impact on the rates of remission of nephrotic syndrome with frexalimab, brivekimig, or rilzabrutinib compared with placebo in participants with primary FSGS or primary MCD aged 16 to 75 years.
Study details for each participant include:
The study duration will be up to 76 weeks. The treatment duration will be 24 weeks. There will be up to 18 visits.
Primary Outcome(s): Percent reduction in urine protein to creatinine ratio (UPCR)
Enrollment: 84 (ESTIMATED)
Lead Sponsor: Sanofi
Start: 2024-12-19 | Primary Completion: 2026-12-23
Systematic review confirms clip anastomosis improves one and two year primary patency rates for arteriovenous fistula creation compared to suture methods
Vascular Clips Outperform Sutures for Dialysis Access Longevity
Related in Nephrology
Precision nutrition offers dynamic optimization for managing patients with chronic liver disease through individualized metabolic profiles
Precision nutrition offers a new way to manage liver disease
This narrative review explores the role of precision nutrition in managing chronic liver disease. The authors argue that tailoring nutrition…
Tailoring nutrition to an individual's unique metabolism could change how doctors manage chronic liver disease and improve patient care.
FDA Approves Terlivaz (terlipressin) for Hepatorenal Syndrome with Rapid Kidney Function Decline
FDA approves new drug Terlivaz for kidney failure in liver disease patients.
The FDA approved Terlivaz (terlipressin) to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney funct…
The FDA approved Terlivaz (terlipressin) to improve kidney function in adults with hepatorenal syndrome, a serious kidney complication of ci…
Intraoperative anesthesia handovers are associated with increased risk of mortality and morbidity in surgical patients
Anesthesia handovers during surgery are linked to higher patient risks
This systematic review and meta-analysis of 14 studies found that intraoperative anesthesia handovers are significantly associated with high…
Research shows that passing anesthesia care between staff during surgery is linked to higher rates of complications and longer stays in inte…
Adolescent physical activity is associated with improved mental and physical health in early adulthood
Adolescent Physical Activity Linked to Better Health in Early Adulthood
This systematic review of 44 articles analyzed the impact of adolescent physical activity on health markers in early adulthood. The authors …
Staying active as a teenager may lead to better physical and mental health outcomes for young adults later in life.
From Other Specialties
Meningeal Immune System Offers New Target for Glioblastoma Immunotherapy
New approach targets the immune system to treat brain tumors
This systematic review explores how targeting the meningeal immune system, including dural lymphatics and rBAMs, could overcome current barr…
A new strategy focuses on the area where brain tumors meet the body's defenses to improve how immunotherapy works for glioblastoma.
A 6 dimension and 42 item system provides early risk assessment for high-risk diabetic feet
Experts Develop New Risk Assessment System for Diabetic Feet
This expert consultation and guideline describes the development of an early risk assessment system for high-risk diabetic feet. The consens…
A new assessment system identifies risk factors like nerve damage and circulation to help manage and prevent complications in patients with …
Rapid advancements in imaging and blood-based biomarkers are transforming the diagnosis and management of ADRD
New guidelines help doctors tell delirium from dementia
This clinical guideline provides a narrative review on the evolving diagnostic and treatment landscape for Alzheimer's disease and related d…
Delirium is acute and fluctuating; dementia is chronic. New guidelines help doctors tell them apart.
ACTH and vigabatrin achieved full seizure control in a patient with Ververi-Brady syndrome
ACTH and Vigabatrin Show Promise for Rare Epilepsy Syndrome
This case report describes a 5-month-old male infant with Ververi-Brady syndrome and infantile epileptic spasms syndrome. The patient achiev…
A new gene variant linked to Ververi-Brady syndrome showed positive results when treated with a combination of ACTH and vigabatrin.